SCHEMBL5537620

SCHEMBL5537620

Cc1ccc(COC(=O)N2CCN([C]=O)CC2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPK1 P28482 3/20 0.42
TP53 P04637 1/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 3/20 0.40
GAA P10253 2/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GRIN2B Q13224 2/20 0.40
ALOX12 P18054 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544257 0.85 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AMAPK1TP53
SCHEMBL5539929 0.83 MEN1 (0.48) L3MBTL1MEN1KMT2AMAPK1LMNA
SCHEMBL5537627 0.82 L3MBTL1 (0.50) L3MBTL1MEN1KMT2AMAPK1TP53
SCHEMBL4678523 0.82 L3MBTL1 (0.49) L3MBTL1MEN1KMT2AMAPK1TP53
SCHEMBL5534521 0.81 MEN1 (0.56) MEN1KMT2ALMNAMAPTGAA
Hydrochloric Acid SCHEMBL4682508 0.81 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AMAPK1TP53
SCHEMBL6744073 0.74 ALDH1A1 (0.61) MEN1KMT2AMAPK1LMNAMAPT
SCHEMBL4866723 0.72 MEN1 (0.62) L3MBTL1MEN1KMT2AGAAHTT
SCHEMBL6667424 0.72 SMN1; SMN2 (0.50) L3MBTL1MEN1KMT2ATP53LMNA
SCHEMBL11467418 0.71 SMN1; SMN2 (0.49) L3MBTL1MEN1KMT2ATP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.